Skip to main content
Portfolio NewsVerge Genomics

Fitz Gate portfolio company Verge Genomics has received positive attention for its first-of-its-kind, cutting-edge design and technology

By March 7, 2024April 5th, 2024No Comments

Biotech has long recognized the benefits of using digital endpoints in clinical trials. Putting it into practice has been another matter. Our CMO, Diego Cadavid, spoke to BioCentury about how Verge is paving the way with a digital-first approach in our proof-of-concept study for ALS, including incorporating an Xbox sensor, to build a digital endpoint.

Read More